DLGAP4

Across TCGA pan-cancer cohorts, DLGAP4 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated DLGAP4 data layer compared with 22 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher DLGAP4 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated DLGAP4 expression acts as an unfavorable survival marker, although some lineages such as LUAD and UCEC show a favorable association.

CCRCC, LUAD, and UCEC are the cancer types where DLGAP4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.752	0.910	.007	14	view →
LUAD	DFS	Median	II,III,IV	0.765	0.251	.014	8	view →
UCEC	DFS	Quartile	II,III,IV	1.000	0.501	.025	6	view →
PDAC	OS	Median	II,III,IV	0.282	0.420	.031	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

DLGAP4–CCRCC (OS)

Open the CCRCC breakdown →